A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

Biotech company Metsera, which develops weight-loss drugs and is backed by ARCH Venture Partners, said on Monday that it is ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

Obesity-drug maker Metsera Inc.'s stock jumped 47% on Friday as the biggest gainer among three initial public offerings bucking a swoon in the equity market to rise in their stock-market debuts Friday ...

Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to ...

Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that will make the kidney disease drug developer the first U.S. biotech ...